期刊文献+

人骨肉瘤组织钙网织蛋白表达及其意义探讨 被引量:1

Expression and significance of calreticulin in human osteosarcoma
原文传递
导出
摘要 目的:探讨钙网织蛋白(calreticulin,CRT)在骨肉瘤组织中的表达与骨肉瘤生长、转移的关系,以及化疗对其表达的影响。方法:取2005-10-01-2010-09-31在山东中医药大学附属医院(15例)、山东大学齐鲁医院(11例)及新汶矿务局集团中心医院(4例)骨科行骨肉瘤切除术、病历资料完整并排除合并其他运动系统肿瘤的骨肉瘤标本30例,其中转移20例,术前化疗者20例。每例标本同时取距离瘤组织>30mm的正常组织作对照。免疫组织化学染色法检测CRT在瘤体组织和正常组织中的表达;RT-PCR法检测CRT在mRNA水平的表达;蛋白质印迹法检测CRT蛋白的表达。结果:CRT主要存在于细胞质内,在所有标本中都有表达。其表达强度为瘤体组织(1.07±0.32)<瘤体周围正常组织(2.68±0.09),P<0.01;肿瘤转移组(0.93±0.21)<未转移组(1.36±0.42),P=0.020;术前未化疗组(0.75±0.21)<术前化疗组(1.24±0.30),P=0.001。CRT mRNA的表达强度为瘤体组织(0.58±0.30)<瘤体周围正常组织(1.48±0.14),P<0.01;肿瘤转移组(0.50±0.22)<未转移组(0.73±0.23),P=0.033;术前未化疗组(0.27±0.13)<术前化疗组(0.74±0.23),P<0.01。CRT蛋白的表达水平为瘤体组织(369.35±14.27)<瘤体周围正常组织(599.23±6.78),P<0.01;肿瘤转移组(361.95±17.37)<未转移组(394.15±17.97),P=0.031;术前未化疗组(288.96±12.86)<术前化疗组(409.54±18.22),P<0.01。结论:CRT的表达在人骨肉瘤组织中降低,其mRNA和蛋白质表达水平下降程度与瘤体是否转移有关,化疗可增加其表达水平。 OBJECTIVE:To detecte the expression of Calreticulin(CRT)in patients with osteosarcoma and analyzed the expression difference in tumor tissue and normal tissue,pre-and post-chemotherapy,metastasis and non-metastasis. According to these results,we analyzed the relationship between the expression of CRT and tumor growth,metatasis,and chemotherapeutics.METHODS:The specimens from 30patients with osteosarcoma were collected as experimental group, in which 10cases were non-metastasis,20were metastasis,and 20were pre-chemotherapy,10were post-chemotherapy. Thirty specimens from normal tissues were collected as control group.The specimens were detected by immunofluorescence staining.Total RNA was extracted from crushed tissue which including experimental and control group,and tested by RT-PCR method.The protein was extracted from crushed tissue including experimental and control group,and analyzed by Western-Blot.RESULTS:CRT was mainly located in intracavity of cell endoplasmic reticulum.The expression level of CRT in normal tissue(2.68±0.09)was higher than that in tumor tissue(1.07±0.32,P〈0.01),the expression level of CRT was higher in non-metastasis group(1.36±0.42)than that in metastasis group(0.93±0.21,P=0.020),and the expression level of CRT was higher in post-chemotherapy group(1.24±0.30)than that in pre-chemotherapy group(0.75±0.21,P=0.001).The expression level of CRT mRNA in normal tissue(1.48±0.14)was higher than that in tumor tissue(0.58±0.30,P〈0.01),in non-metastasis group(0.73±0.23)it was higher than in metastasis group(0.50± 0.22,P=0.033)and in post-chemotherapy group(0.74±0.23)it was higher than in pre-chemotherapy group(0.27± 0.13,P〈0.01).The expression level of CRT protein in normal tissue(599.23±6.78)was higher than that in tumor tissue(369.35±14.27,P〈0.01),the expression level was higher in non-metastasis group(394.15±17.97)than that in metastasis group(361.95±17.37,P=0.031),and the expression level of CRT in post-chemotherapy group(409.54± 18.22)was higher than that in pre-chemotherapy group(288.96±12.86,P〈0.01).CONCLUSION:The expression level of CRT in normal tissue around the tumor is higher than that of tumor tissue,in non-metastasis group it is higher than that of metastasis group,post-chemotherapy group is higher than that of pre-chemotherapy group.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第10期757-761,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 骨肉瘤 钙网织蛋白 免疫荧光组织化学染色 逆转录聚合酶链反应 蛋白质印迹 osteosarcoma calreticulin CRT immunofluorescence staining RT-PCR western-blot
  • 相关文献

参考文献15

  • 1Zhang YK, Yang Z, Li X, et al. Custom prosthetic reconstruction for proximal tibial osteosarcoma with proximal tibiofibular joint involved[J]. Surg Oncol, 2008,17(2) : 87-95.
  • 2邢旻琰,何爱娜,余文悉,陈杰,张惠箴,沈赞.骨肉瘤组织XIAP蛋白表达临床意义的研究[J].中华肿瘤防治杂志,2013,20(3):214-216. 被引量:5
  • 3刘郁东,郑启新,吴宏斌,郭晓东,李景峰,郝少飞.缺氧对骨肉瘤细胞MG63核干细胞因子表达调节及其机制的探讨[J].中华肿瘤防治杂志,2013,20(3):191-195. 被引量:1
  • 4Lwin ZM, Guo CH,.Salim A, et al. Clinieopathoiogieal signifi cance of calreticulin in breast invasive duetal carcinoma[J]. Mod Pathol, 2010,23(12) : 1559-1566.
  • 5Du XL, Yang H, Liu SG, et al. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma[J]. Oncogene, 2009,28(42) : 3714-3722.
  • 6Liu R, Gong J, Chen J, et al. Calreticulin as a potential diagnostic biomarker for lung eancer[J].Cancer Immunol Immunother, 2012,61(6) :855 -864.
  • 7Wang HT, Lee HI, Guo J H, et al. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of im- munotherapy by up-regulating the endothelial expression of ad- hesion moleeules[J]. Int J Cancer, 2012,130(12) : 2892-2902.
  • 8Zhang YK,Zhang XH,Li JM,et al. A proteomic study on a hu- man osteosarcoma cell line Saos-2 treated with diallyl trisulfide [J]. Anticancer Drugs, 2009,20 (8) : 702-712.
  • 9Hao YK, Zhang YK, Yang ZP, et al. The accuracy of magnetic resonance imaging (MRD in determining osteotomy plane of os- teosarcoma[J]. Orthopedics, 2008,31(6) : 544.
  • 10Lee AS. The glucose-regulated proteins : stress inductionand clin- ical applications[J]. Trends Biochern Sci,2001,26(8) :504-510.

二级参考文献54

  • 1董丽,许青霞.尿中Cy21.1在膀胱癌诊断中应用[J].实用医技杂志,2006,13(1):54-54. 被引量:2
  • 2钟春燕,柳长柏.钙网蛋白及其与肿瘤的关系[J].生命的化学,2007,27(2):172-174. 被引量:5
  • 3Antor AF, Hartge P, Hoover RN, et al. Epidemiological character istie of squamous cell carcinoma and adenocarcinoma of the blad der[J]. Cancer Res,1998,48(13) :3853-3855.
  • 4Gray M,Sims TW. NMP-22 for bladder cancer screening and sur veillance[J]. Urol Nurs,2004,24(3) : 171-172.
  • 5Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calretieulin as a marker for bladder cancer and evalua- tion of the diagnostic accuracy of its detection in urine[J]. Clin Chem, 2004,50 (5) : 857-866.
  • 6Gelebart P, Opas M, Michalak ML. Calreticulin, a Ca +-binding chaperone of the endoplasrnic reticulm[J]. Int J Bioehem Cell Biol, 2005,37 (2) : 260-266.
  • 7Iwaki H,Kageyama S,Isono T,et al. Diagnostic potential in blad der cancer of a panel of tumor markers(calreticulin,gamma-synu clein,and catechol-o-methyltransferase) identified by proteomic a nalysis[J]. Cancer Sci,2004,95(12) :955-961.
  • 8Dey P. Urinary markers of bladder carcinoma[J]. Clin Chem Ac ta, 2004,340(12) : 803-810.
  • 9Ecke TH. Focus on urinary bladder cancer markers: a review[J]. Minerva Urol Nefrol,2008,60(4):237-246.
  • 10Eissa S, Kenawy G, Swellam M, et al. Compararison of eytokera- tin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder careinoma[J]. Clin Bioehem, 2004,37 (9) : 803- 810.

共引文献9

同被引文献19

  • 1Morrow JJ,Khanna C Osteosarcoma genetics and epigenetics:emerging biology and candidate therapies [J]. Crit Rev Oncog,2015,20(3-4):173-197.
  • 2Moriarity BS,Otto GM ,Rahrmann EP,et al. A SleepingBeauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis [J].Nat Genet,2015,47(6) ;615-624.
  • 3Liu F,Chang H,Xu W,et al. The effects of LivinshRNAon the response to cisplatin in HepG2 cells [J]. Oncol Lett,2015,10(5):2957-2961.
  • 4Gurung P, Kanneganti TD. Novel Roles for Caspase-8 in*IL-lp and Inflammasome Regulation [J]. Am J Pathol,2015,185(l):17-25.
  • 5隋官杰,曲珍,罗含笑,等.骨膜骨肉瘤病理组织学诊断体会[C]//全国软组织和骨肿瘤病理诊断学术研讨会论文汇编,2004:121.
  • 6Huang S,0kamoto K,Yu C,et aL p62/Sequestosome~l Up-regulation Promotes ABT -263 -induced Caspase -8Aggregation/Activation on the Autophagosome [I]. J Biol Chem,2013,288(47):33654-33666.
  • 7Basu -Roy U,Basilico C,Mansukhani A. Perspectives oncancer stem cells in osteosarcoma [J]. Cancer lett, 2013,338(1):158-167.
  • 8叶建平,余飞,徐文玲,史三忠,孙蕾,刘家赵.体部伽玛刀治疗骨肉瘤肺转移疗效分析[J].中国医药科学,2011,1(17):21-22. 被引量:4
  • 9蔡玉亮,崔森,李占全,王红心,冀林华,柴克霞.慢性高原病患者骨髓造血细胞凋亡及caspase-8和caspase-9表达研究[J].中华血液学杂志,2011,32(11):762-765. 被引量:15
  • 10祁伟祥,何爱娜,汤丽娜,沈赞,姚阳.儿童骨肉瘤与青年骨肉瘤临床特点比较及预后影响因素分析[J].中国肿瘤临床,2011,38(21):1330-1334. 被引量:10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部